Epidemiology of candidaemia and invasive candidiasis. A changing face

Revista Iberoamericana de Micologia

Volumn 31, Issue 1, 2014, Pages 42-48

  Quindós, Guillermo ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Candida albicans; Candida krusei; Candida parapsilosis; Candida tropicalis; Candidaemia; Epidemiology; Invasive candidiasis

Indexed keywords

CANDIDA ALBICANS; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDAEMIA; CANDIDEMIA; CANDIDIASIS INVASIVE; EPIDEMIOLOGÍA; EPIDEMIOLOGY; INVASIVE CANDIDIASIS;

ADULT; AGE DISTRIBUTION; CANDIDA; CANDIDEMIA; CANDIDIASIS, INVASIVE; CHILD; CROSS INFECTION; FEMALE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; MORBIDITY; SEX DISTRIBUTION; SPECIES SPECIFICITY; WORLD HEALTH; YOUNG ADULT;

EID: 84893791409     PISSN: 11301406     EISSN: 21739188     Source Type: Journal    
DOI: 10.1016/j.riam.2013.10.001     Document Type: Short Survey

References (67)

1. Almirante B., Proyecto CandiPop Estudio multicéntrico nacional sobre candidemia: presentación de estudios clínicos. IV Jornada científica del Grupo de Estudio de Micología Médica de la SEIMC 2013.
2. Almirante B., Rodríguez D., Cuenca-Estrella M., Almela M., Sanchez F., Ayats J., et al. Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: case-control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2006, 44:1681-1685.
3. Almirante B., Rodríguez D., Park B.J., Cuenca-Estrella M., Planes A.M., Almela M., et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona Spain, from 2002 to 2003. J Clin Microbiol 2005, 43:1829-1835.
4. Arendrup M.C., Bruun B., Christensen J.J., Fuursted K., Johansen H.K., Kjaeldgaard P., et al. National surveillance of fungemia in Denmark (2004 to 2009). J Clin Microbiol 2011, 49:325-334.
5. Arendrup M.C., Fuursted K., Gahrn-Hansen B., Jensen I.M., Knudsen J.D., Lundgren B., et al. Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility. J Clin Microbiol 2005, 43:4434-4440.
6. Arendrup M.C., Fuursted K., Gahrn-Hansen B., Schønheyder H.C., Knudsen J.D., Jensen I.M., et al. Semi-national surveillance of fungaemia in Denmark 2004-2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility. Clin Microbiol Infect 2008, 14:487-494.
7. Asmundsdóttir L.R., Erlendsdóttir H., Gottfredsson M. Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland. J Clin Microbiol 2002, 40:3489-3492.
8. Asmundsdottir L.R., Erlendsdottir H., Gottfredsson M. Nationwide study of candidemia, antifungal use and antifungal drug resistance in Iceland, 2000-2011. J Clin Microbiol 2013, 51:841-848.
9. Ben-Ami R., Rahav G., Elinav H., Kassis I., Shalit I., Gottesman T., et al. Distribution of fluconazole-resistant Candida bloodstream isolates among hospitals and in patient services in Israel. Clin Microbiol Infect 2013, 19:752-756.
10. Bergamasco M.D., Garnica M., Colombo A.L., Nucci M. Epidemiology of candidemia in patients with hematologic malignancies and solid tumours in Brazil. Mycoses 2013, 56:256-263.
11. Boonyasiri A., Jearanaisilavong J., Assanasen S. Candidemia in Siriraj Hospital: epidemiology and factors associated with mortality. J Med Assoc Thai 2013, 96(Suppl. 2):S91-S97.
12. Cantón E., Pemán J., Quindós G., Eraso E., Miranda-Zapico I., Álvarez M., et al. Prospective multicenter study of the epidemiology, molecular identification, and antifungal susceptibility of Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis isolated from patients with candidemia. Antimicrob Agents Chemother 2011, 55:5590-5596.
13. Chen S., Slavin M., Nguyen Q., Marriott D., Playford E.G., Ellis D., et al. Active surveillance for candidemia. Australia Emerg Infect Dis 2006, 12:1508-1516.
14. Cisterna R., Ezpeleta G., Telleria O. Nationwide sentinel surveillance of bloodstream Candida infections in 40 tertiary care hospitals in Spain. J Clin Microbiol 2010, 48:4200-4206. Spanish Candidemia Surveillance Group, [Erratum in: J Clin Microbiol 2011;49:1193. Retraction in: J Clin Microbiol. 2011; 49:1193].
15. Colombo A.L., Garnica M., Aranha Camargo L.F., Da Cunha C.A., Bandeira A.C., Borghi D., et al. Candida glabrata: an emerging pathogen in Brazilian tertiary care hospitals. Med Mycol 2013, 51:38-44.
16. Colombo A.L., Nucci M., Park B.J., Nouér S.A., Arthington-Skaggs B., da Matta D.A., et al. Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. J Clin Microbiol 2006, 44:2816-2823.
17. Córdoba S., Vivot W., Bosco-Borgeat M.E., Taverna C., Szusz W., Murisengo O., et al. Species distribution and susceptibility profile of yeasts isolated from blood cultures: results of a multicenter active laboratory-based surveillance study in Argentina. Rev Argent Microbiol 2011, 43:176-185.
18. Correia A., Sampaio P., James S., Pais C. Candida bracarensis sp. nov., a novel anamorphic yeast species phenotypically similar to Candida glabrata. Int J Syst Evol Microbiol 2006, 56:313-317.
19. Cortés J.A., Reyes P., Gómez C., Buitrago G., Leal A.L. Fungal bloodstream infections in tertiary care hospitals in Colombia. Rev Iberoam Micol 2011, 28:74-78. GREBO.
20. Das I., Nightingale P., Patel M., Jumaa P. Epidemiology, clinical characteristics, and outcome of candidemia: experience in a tertiary referral center in the UK. Int J Infect Dis 2011, 15:e759-e763.
21. Diekema D., Arbefeville S., Boyken L., Kroeger J., Pfaller M. The changing epidemiology of healthcare-associated candidemia over three decades. Diagn Microbiol Infect Dis 2012, 73:45-48.
22. Diekema D.J., Messer S.A., Brueggemann A.B., Coffman S.L., Doern G.V., Herwaldt L.A., et al. Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol 2002, 40:1298-1302.
23. Ece G., Samlioglu P., Akkoclu G., Atalay S., Kose S. The evaluation of the distribution of yeast like fungi 'Candida Species' at a tertiary care center in western Turkey. Int J Med Sci 2012, 9:617-620.
24. Ericsson J., Chryssanthou E., Klingspor L., Johansson A.G., Ljungman P., Svensson E., et al. Candidaemia in Sweden: a nationwide prospective observational survey. Clin Microbiol Infect 2013, 19:E218-E221.
25. Forrest G.N., Weekes E., Johnson J.K. Increasing incidence of Candida parapsilosis candidemia with caspofungin usage. J Infect 2008, 56:126-129.
26. González G.M., Elizondo M., Ayala J. Trends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monterrey Mexico, to seven antifungal agents: results of a 3-year (2004 to 2007) surveillance study. J Clin Microbiol 2008, 46:2902-2905.
27. Grim S.A., Berger K., Teng C., Gupta S., Layden J.E., Janda W.M., et al. Timing of susceptibility-based antifungal drug administration in patients with Candida bloodstream infection: correlation with outcomes. J Antimicrob Chemother 2012, 67:707-714.
28. Hachem R., Hanna H., Kontoyiannis D., Jiang Y., Raad I. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer 2008, 112:2493-2499.
29. Hajjeh R.A., Sofair A.N., Harrison L.H., Lyon G.M., Arthington-Skaggs B.A., Mirza S.A., et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004, 42:1519-1527.
30. Kao A.S., Brandt M.E., Pruitt W.R., Conn L.A., Perkins B.A., Stephens D.S., et al. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis 1999, 29:1164-1170.
31. Kreusch A., Karstaedt A.S. Candidemia among adults in Soweto South Africa, 1990-2007. Int J Infect Dis 2013, 17:e621-e623.
32. Lai C.C., Chu C.C., Wang C.Y., Tsai H.Y., Cheng A., Lee Y.C., et al. Association between incidence of candidaemia and consumption of antifungal agents at a medical centre in Taiwan. Int J Antimicrob Agents 2012, 40:349-353.
33. Laupland K.B., Gregson D.B., Church D.L., Ross T., Elsayed S. Invasive Candida species infections: a 5 year population-based assessment. J Antimicrob Chemother 2005, 56:532-537.
34. Leung A.Y., Chim C.S., Ho P.L., Cheng V.C., Yuen K.Y., Lie A.K., et al. Candida tropicalis fungaemia in adult patients with haematological malignancies: clinical features and risk factors. J Hosp Infect 2002, 50:316-319.
35. Lin M.Y., Carmeli Y., Zumsteg J., Flores E.L., Tolentino J., Sreeramoju P., et al. Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case control study. Antimicrob Agents Chemother 2005, 49:4555-4560.
36. Lockhart S.R., Iqbal N., Cleveland A.A., Farley M.M., Harrison L.H., Bolden C.B., et al. Species identification and antifungal susceptibility testing of Candida bloodstream isolates from population-based surveillance studies in two U.S. cities from 2008 to 2011. J Clin Microbiol 2012, 50:3435-3442.
37. Lockhart S.R., Messer S.A., Gherna M., Bishop J.A., Merz W.G., Pfaller M.A., et al. Identification of Candida nivariensis and Candida bracarensis in a large global collection of Candida glabrata isolates: comparison to the literature. J Clin Microbiol 2009, 47:1216-1217.
38. López Moral L., Tiraboschi I.N., Schijman M., Bianchi M., Guelfand L., Cataldi S., et al. Fungemias en hospitales de la Ciudad de Buenos Aires. Rev Iberoam Micol 2012, 29:144-149.
39. López-Soria L.M., Bereciartua E., Santamaría M., Soria L.M., Hernández-Almaraz J.L., Mularoni A., et al. First case report of catheter-related fungemia by Candida nivariensis in the Iberian Peninsula. Rev Iberoam Micol 2013, 30:69-71.
40. Miranda-Zapico I., Eraso E., Hernández-Almaraz J.L., López-Soria L.M., Carrillo-Muñoz A.J., Hernández-Molina J.M., et al. Prevalence and antifungal susceptibility patterns of new cryptic species inside the species complexes Candida parapsilosis and Candida glabrata among blood isolates from a Spanish tertiary hospital. J Antimicrob Chemother 2011, 66:2315-2322.
41. Moran C., Grussemeyer C.A., Spalding J.R., Benjamin D.K., Reed S.D. Candida albicans and non-albicans bloodstream infections in adult and pediatric patients: comparison of mortality and costs. Pediatr Infect Dis J 2009, 28:433-435.
42. Moran C., Grussemeyer C.A., Spalding J.R., Benjamin D.K., Reed S.D. Comparison of costs, length of stay, and mortality associated with Candida glabrata and Candida albicans bloodstream infections. Am J Infect Control 2010, 38:78-80.
43. Moretti M.L., Trabasso P., Lyra L., Fagnani R., Resende M.R., de Oliveira Cardoso L.G., et al. Is the incidence of candidemia caused by Candida glabrata increasing in Brazil? Five-year surveillance of Candida bloodstream infection in a university reference hospital in southeast Brazil. Med Mycol 2013, 51:225-230.
44. Nucci M., Queiroz-Telles F., Alvarado-Matute T., Tiraboschi I.N., Cortes J., Zurita J., et al. Epidemiology of candidemia in Latin America: a laboratory-based survey. PLoS One 2013, 8:e59373.
45. Nucci M., Thompson-Moya L., Guzmán-Blanco M., Tiraboschi N., Cortés J.A., Echevarria J., et al. Recommendations for the management of candidemia in adults in Latin America. Rev Iberoam Micol 2013, 30:179-188.
46. Odds F.C., Hanson M.F., Davidson A.D., Jacobsen M.D., Wright P., Whyte J.A., et al. One year prospective survey of Candida bloodstream infections in Scotland. J Med Microbiol 2007, 56:1066-1075.
47. Pemán J., Cantón E., Miñana J.J., Florez J.A., Echeverria J., Ortega D.N., et al. Changes in the epidemiology of fungaemia and fluconazole susceptibility of blood isolates during the last 10 years in Spain: results from the FUNGEMYCA study. Rev Iberoam Micol 2011, 28:91-99.
48. Pemán J., Cantón E., Quindós G., Eraso E., Alcoba J., Guinea J., et al. Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey. J Antimicrob Chemother 2012, 67:1181-1187.
49. Pfaller M.A., Diekema D.J., Gibbs D.L., Newell V.A., Barton R., Bijie H., et al. Geographic variation in the frequency of isolation and fluconazole and voriconazole susceptibilities of Candida glabrata: an assessment from the ARTEMIS DISK Global Antifungal Surveillance Program. Diagn Microbiol Infect Dis 2010, 67:162-171.
50. Pfaller M.A., Moet G.J., Messer S.A., Jones R.N., Castanheira M. Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009. Antimicrob Agents Chemother 2011, 55:561-566.
51. Playford E.G., Marriott D., Nguyen Q., Chen S., Ellis D., Slavin M., et al. Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans Candida spp. Crit Care Med 2008, 36:2034-2039.
52. Playford E.G., Nimmo G.R., Tilse M., Sorrell T.C. Increasing incidence of candidaemia: long-term epidemiological trends, Queensland Australia, 1999-2008. J Hosp Infect 2010, 76:46-51.
53. Poikonen E., Lyytikäinen O., Anttila V.J., Koivula I., Lumio J., Kotilainen P., et al. Secular trend in candidemia and the use of fluconazole in Finland, 2004-2007. BMC Infect Dis 2010, 10:312.
54. Poikonen E., Lyytikäinen O., Anttila V.J., Ruutu P. Candidemia in Finland, 1995-1999. Emerg Infect Dis 2003, 9:985-990.
55. Presterl E., Daxböck F., Graninger W., Willinger B. Changing pattern of candidaemia 2001-2006 and use of antifungal therapy at the University Hospital of Vienna, Austria. Clin Microbiol Infect 2007, 13:1072-1076.
56. Quindós G. Candidemias y candidiasis invasivas nosocomiales. Med Clin (Barc) 2010, 134:17-19.
57. Quindós G., Sánchez-Vargas L.O., Villar-Vidal M., Eraso E., Alkorta M., Hernández-Almaraz J.L. Activities of fluconazole and voriconazole against bloodstream isolates of Candida glabrata and Candida krusei: a 14-year study in a Spanish tertiary medical centre. Int J Antimicrob Agents 2008, 31:266-271.
58. Sampaio-Camargo T.Z., Marra A.R., Silva C.V., Cardoso M.F., Martino M.D., Camargo L.F., et al. Secular trends of candidemia in a tertiary care hospital. Am J Infect Control 2010, 38:546-551.
59. Sandven P., Bevanger L., Digranes A., Haukland H.H., Mannsåker T., Gaustad P., et al. Candidemia in Norway (1991 to 2003): results from a nationwide study. J Clin Microbiol 2006, 44:1977-1981.
60. Santolaya M.E., de Queiroz Telles F., Alvarado Matute T., Colombo A.L., Zurita J., Tiraboschi N., et al. Recommendations for the management of candidemia in neonates in Latin America. Rev Iberoam Micol 2013, 30:158-170.
61. Tortorano A.M., Kibbler C., Peman J., Bernhardt H., Klingspor L., Grillot R. Candidaemia in Europe: epidemiology and resistance. Int J Antimicrob Agents 2006, 27:359-366.
62. Tortorano A.M., Peman J., Bernhardt H., Klingspor L., Kibbler C.C., Faure O., et al. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 2004, 23:317-322.
63. Tortorano A.M., Prigitano A., Biraghi E., Viviani M.A. The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: in vitro susceptibility of 375 Candida albicans isolates and biofilm production. J Antimicrob Chemother 2005, 56:777-779. FIMUA-ECMM Candidaemia Study Group.
64. Tragiannidis A., Fegeler W., Rellensmann G., Debus V., Müller V., Hoernig-Franz I., et al. Candidaemia in a European Paediatric University Hospital: a 10-year observational study. Clin Microbiol Infect 2012, 18:E27-E30.
65. Wenzel R.P., Edmond M.B. The impact of hospital-acquired bloodstream infections. Emerg Infect Dis 2001, 7:174-177.
66. Wenzel R.P., Gennings C. Bloodstream infections due to Candida species in the intensive care unit: identifying especially high-risk patients to determine prevention strategies. Clin Infect Dis 2005, 41(Suppl. 6):S389-S393. [Erratum in: Clin Infect Dis 2005;41(Suppl. 6):1694].
67. Wu J.Q., Zhu L.P., Ou X.T., Xu B., Hu X.P., Wang X., et al. Epidemiology and risk factors for non-Candida albicans candidemia in non-neutropenic patients at a Chinese teaching hospital. Med Mycol 2011, 49:552-555.